Patients in the PD-L1-high-actived and PD-L1-high-exhausted groups were found to have a significantly higher overall survival and better response to chemotherapy and immunotherapy, suggesting that cancer therapeutics can be tailored based on the immune subgroups of the tumour microenvironment. This evidence concerns the gene CD274 and neoplasm.